Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
NCT00237120 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2009-11-23
Summary
This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.
Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
Interventions
- DRUG
-
Imatinib
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Novartis
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 15 Years
- Max Age
- 74 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-11-30
- Completion
- 2007-06-30
More Related Trials
-
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490 ·Status: TERMINATED ·Phase: PHASE2
-
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00101088 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
NCT01011998 ·Status: WITHDRAWN ·Phase: PHASE2
-
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
NCT00028847 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
NCT01394666 ·Status: COMPLETED
-
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT02130557 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
NCT00632255 ·Status: COMPLETED
-
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
NCT00130195 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
NCT01221376 ·Status: UNKNOWN ·Phase: PHASE2
-
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
NCT00896129 ·Status: COMPLETED
-
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
NCT00574873 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
NCT00428909 ·Status: COMPLETED ·Phase: PHASE1
-
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
NCT00123474 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
NCT00219726 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
NCT00171158 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
NCT03241199 ·Status: UNKNOWN ·Phase: PHASE2
-
Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00769327 ·Status: COMPLETED ·Phase: PHASE2
-
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
NCT00386373 ·Status: COMPLETED ·Phase: NA
-
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia
NCT03214718 ·Status: UNKNOWN ·Phase: NA
-
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
NCT02115672 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT00519090 ·Status: TERMINATED ·Phase: PHASE3